Effect of Protease Inhibitor-Based Highly Active Antiretroviral Therapy on Survival in HIV-Associated Advanced Kaposi's Sarcoma Patients Treated with Chemotherapy

REFERENCES

• Gill PS, Akil B, Colletti P, et al. Pulmonary Kaposi's sar-coma: clinical findings and results of therapy. Am J Med. 1989;87(1):57–61.
   PubMed Web of Science ®Google Scholar
• Tavio M, Nasti G, Spina M, et al. Highly active antiretroviral therapy in HIV-related Kaposi's sarcoma. Ann Oncol. 1998;9(8):923.
   PubMed Web of Science ®Google Scholar
• Murphy M, Armstong D, Sepkowitz KA, et al. Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-1 protease inhibitor. AIDS. 1997;11(2):261–262.
   PubMed Web of Science ®Google Scholar
• Conant MA, Opp KM, Poretz D, Mills RG. Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonovir. AIDS. 1997;11(10):1300–1301.
   PubMed Web of Science ®Google Scholar
• Martinelli C, Zazzi M, Ambu S, et al. Complete regression of AIDS-related Kaposi's sarcoma-associated human her-pesvirus-8 during therapy with indinavir. AIDS. 1998;12(13):1717–1719.
   PubMed Web of Science ®Google Scholar
• Wit FW, Sol CJ, Renwick N, et al. Regression of AIDS-related Kaposi's sarcoma associated with clearance of human herpesvirus-8 from peripheral blood mononuclear cells following initiation of antiretroviral therapy. AIDS. 1998;12(2):218–219.
   PubMed Web of Science ®Google Scholar
• Burdick AE, Carmichael C, Rady PL, et al. Resolution of Kaposi's sarcoma associated with undetectable level of human herpesvirus 8 DNA in a patient with AIDS after protease inhibitor therapy. J Am Acad Dermatol. 1997;37(4):648–649.
   PubMed Web of Science ®Google Scholar
• Jacobsen LP, Yamashita TE, Detels R. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and nonHodgkin's lymphomas among HIV-1-infected indi-viduals. Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 1999;21\(suppl 1):534–541.
   Google Scholar
• Lebbe C, Blum L, Pellet C, et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS. 1998;12(7):F45–49.
   PubMed Web of Science ®Google Scholar
• Aboulafia D. Regression of acquired immunodeficiency syndrome-related pulmonary Kaposi's sarcoma after highly active antiretroviral therapy. Mayo Clin Proc. 1998;73:439–443.
   PubMed Web of Science ®Google Scholar
• Winceslaus J. Regression of AIDS-related pleural effusion with HAART. Highly active antiretroviral therapy. Int J STD AIDS. 1998;9(6):368–370.
   PubMed Web of Science ®Google Scholar
• Parra R, Leal M, Delgado J, et al. Regression of invasive AIDS-related Kaposi's sarcoma following antiretroviral therapy. Clin Infect Dis. 1998;26(1):218–219.
   PubMed Web of Science ®Google Scholar
• Blum L, Pellet C, Agbalika F, et al. Complete remission of AIDS-related Kaposi's sarcoma associated with undetect-able human herpesvirus-8 sequences during anti-HIV pro-tease therapy. AIDS. 1997;11(13):1653–1655.
   PubMed Web of Science ®Google Scholar
• Holkova B, Takeshita K, Cheng DM, et al. Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy. J Clin Oncol. 2001;19(18):3848–3851.
   PubMed Web of Science ®Google Scholar
• Levine AM, Tulpule A. Clinical aspects and management of AIDS-related Kaposi's sarcoma. Eur J Cancer. 200137(10)1288–1295.
   Web of Science ®Google Scholar
• Antman K, Chang Y. Kaposi's sarcoma. N Engl J Med. 2000;342(14):1027–1038.
   PubMed Web of Science ®Google Scholar
• Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sar-coma: results of a randomized phase III clinical trial. J Clin Oncol. 1998;16(7):2445–2451.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute Common Toxicity Criteria. (Na-tional Cancer Institute Web site). Available at: http://ctep.cancer.gov/reporting/ctc.html. Accessed August 3, 2002.
   Google Scholar
• Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uni-form evaluation, response, and staging criteria. AIDS Clini-cal Trials Group Oncology Committee. J Clin Oncol. 1989;7(9):1201–1207.
   PubMed Web of Science ®Google Scholar
• Krown SE, Testa MA, Huang J. AIDS-related Kaposi's sar-coma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1997;15(9):3085–3092.
   PubMed Web of Science ®Google Scholar
• Pati S, Pelser CB, Dufraine J, et al. Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sar-coma. Blood. 2002;99(10):3771–3779.
   PubMed Web of Science ®Google Scholar
• Sgadari C, Barillari G, Toschi E, et al. HIV protease inhibi-tors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med. 2002;8(3):225–232.
   PubMed Web of Science ®Google Scholar
• TireIli U, Juzbasic G, Vultaggio G, et al. Highly active antiretroviral therapy (HAART) is an effective anti-Kaposi's Sarcoma (KS) therapy after debulking chemotherapy (CT). Proc ASCO. 2001;20(2):365a.
   Google Scholar
• Ensoli B, Sgadar C, Barillari G, et al. Biology of Kaposi's sarcoma. Eur J Cancer. 200137(10):1251–1269.
   Web of Science ®Google Scholar
• Leigh BR, Burke PA, Hong AM, et al. Preclinical evaluation of chimeric L6 antibody for the treatment of Kaposi's sar-coma with radioimmunotherapy. Cancer Biother Radiopharm. 1999;14(2):113–119.
   PubMed Web of Science ®Google Scholar
• Little RF, Wyvill KM, Pluda JM, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol. 2000;18(13):2593–2602.
   PubMed Web of Science ®Google Scholar
• Blankaert D, Simonart T, Van Vooren JP, et al. Constitutive release of metalloproteinase-9 (92-kd type IV collagenase) by Kaposi's sarcoma cells. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(3):203–209.
   PubMedGoogle Scholar
• TireIli U, Bernardi D. Impact of HAART on the clinical management of AIDS-related cancers. Eur J Cancer. 2001;37(10):1320–1324.
   PubMed Web of Science ®Google Scholar
• Vaccher E, Di Gennaro G, Nasti G, et al. HAART is effective as anti-Kaposi's sarcoma therapy only after remission has been induced by chemotherapy. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;22(4):407–408.
   Google Scholar
• Boivin G, Gaudreau A, Routy JP. Evaluation of the human herpesvirus 8 DNA load in blood and Kaposi's sarcoma skin lesions from AIDS patients on highly active antiretroviral therapy. AIDS. 2000;14(13):1907–1910.
   PubMed Web of Science ®Google Scholar